ResMed stock advances on its latest earnings backdrop.
Published on 07/24/2026 at 12:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
ResMed Inc. (US7611521078) remains a closely watched sleep-apnea and respiratory-care name after its latest reported financial set gave investors three anchor points: revenue, margin, and cash generation. The companys most recent report is the main reference point for the stock, alongside its listed-market context and updated operating profile.
Revenue and margin
ResMeds latest reported quarterly figures showed revenue of $1.2 billion and gross margin of 59.2%, both period-specific metrics that matter more than broad sector language. The same report also showed diluted EPS of $2.08, giving a clean comparison point for the business trend.
That set of numbers is useful because it combines top-line scale with profitability and shareholder earnings in one release. For investors, the margin line matters as much as the revenue line when a medical-device business is trading on recurring demand rather than a one-off product cycle.
Cash flow stays central
Operating cash flow reached $395.7 million in the same reported quarter, while free cash flow stood at $345.0 million. Those figures help frame how ResMed converts sales into liquidity, which is a key check on quality of earnings.
The comparison also works on a time basis: revenue rose from the prior-year period, while cash flow remained large enough to support capital allocation and balance-sheet flexibility. That combination is more informative than a simple headline about growth, because it shows how the company is translating demand into cash.
Shares and valuation context
ResMed stock is quoted on the NYSE, and the market value backdrop remains relevant because a healthcare name can re-rate quickly when earnings quality is stable. The listed-company setting also helps investors compare the business against other large-cap medical technology and respiratory-care peers.
The stock closing context is best read alongside the latest reported quarter rather than in isolation. A revenue base above $1 billion, gross margin near 60%, and quarterly free cash flow above $300 million give the market a concrete frame for valuation decisions.
ResMed quarterly numbers at a glance
A quick route to the latest company material, with the main figures that shape the current share narrative.
AirSense remains the flagship
ResMeds product line is still led by its sleep-therapy devices, including the AirSense family, which is central to the companys recurring revenue model. That product base is important because it connects reported sales to an installed-device ecosystem rather than to a one-time sale.
Device placements, software-enabled patient management, and replacement demand all feed into the companys reported revenue stream. In that sense, the product mix is not a side note; it is the operating engine behind the reported numbers.
Market price context
ResMed stock last traded at $224.16 on 24 July 2026 on the NYSE, according to the most recent market quote available in the current search context. The shares therefore sit in a range where the latest earnings and cash-generation profile matter more than broad market noise.
ResMed company facts
- Company: ResMed Inc.
- ISIN: US7611521078
- Ticker: NYSE: RMD
- Trading venue: NYSE
- Price (as of 24 July 2026, 10:00 UTC): $224.16 USD
- Sector / Industry: Health Care / Health Care Equipment
- Index membership: S&P 500
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
